摘要
目的观察康柏西普治疗葡萄膜大脑炎(Vogt-Koyanagi-Harada,VKH)综合征的短期疗效和安全性。方法选择2015年4月至2018年3月在我院确诊的VKH综合征患者11例(18眼),在常规皮质类固醇激素和免疫抑制剂治疗的同时行康柏西普(0.05 mL)玻璃体内注射,同一患者的左右眼注射时间间隔7~14d,于治疗后1 d、3d和14d观察最佳矫正视力(best corrected visual acuity,BCVA)及黄斑中心凹脉络膜厚度的变化。结果 VKH综合征患眼治疗前BCVA为0.13±0.21,治疗后1d、3d、14 d BCVA分别为0.17±0.22、0.21±0.37、0.29±0.51;治疗后1 d与治疗前比较差异无统计学意义(P>0.05);治疗后3 d、14 d与治疗前比较差异均有统计学意义(均为P<0.05)。治疗前黄斑中心凹脉络膜厚度为(566.71±39.28)μm;治疗后1d、3d、14d黄斑中心凹脉络膜厚度分别为(499.13±26.48)μm、(276.54±87.42)μm、(244.08±61.28)μm,与治疗前比较差异均有统计学意义(均为P<0.05)。结论常规皮质类固醇激素和免疫抑制剂治疗的同时行康柏西普玻璃体内注射治疗VKH综合征安全有效,可迅速促进视网膜下液吸收、降低黄斑中心凹脉络膜厚度,短期内可迅速改善视功能。
Objective To observe the short-term efficacy and safety of conbercept in the treatment of Vogt-Koyanagi-Harada(VKH) syndrome.Methods From April 2015 to March 2018,11 patients(18 eyes) of VKH received intravitreal injection of conbercept(0.05 mL) and at the same time underwent conventional corticosteroid and immunosuppressive therapy.The left and right eye injection time interval of the same patient was 7-14 d.Then,the best corrected visual acuity(BCVA) and subfoveal choroidal thickness were recorded 1 day,3 days and 14 days after treatment.Results In VKH patients,the BCVA was 0.13±0.21 before treatment.the BCVA of 1 day,3 days and 14 days after treatment were 0.17±0.22,0.21±0.37 and 0.29±0.51,respectively.There was no significant difference between before and after treatment at 1 day(P>0.05).There were significant differences between before and after treatment at 3 days and 14 days(both P<0.05).The subfoveal choroidal thickness was(499.13±26.48)μm,(276.54±87.42)μm and(244.08±61.28)μm at 1 day,3 days and 14 days after treatment,respectively,which were significantly lower than those before treatment [(566.71±39.28)μm](all P<0.05).Conclusion It is safe and effective for conbercept injection in the treatment of VKH at the same time with conventional corticosteroid and immunosuppressive therapy.It can rapidly promote the absorption of subretinal fluid,reduce subfoveal choroidal thickness and improve visual function in short term.
作者
方腾
文晓霞
FANG Teng;WEN Xiao-Xia(the Department of Ophthalmology,the People’s Hospital of Chongqing Kaizhou District,Chongqing 405400,China)
出处
《眼科新进展》
CAS
北大核心
2019年第6期561-563,共3页
Recent Advances in Ophthalmology
基金
重庆市卫生计生委2017科研指导项目(编号:2017ZBXM063)~~
